乌司奴单克隆抗体在合并特殊情况克罗恩病患者中治疗有效性和安全性的病例分析  

The efficacy and safety of ustekinumab in special cases with Crohn′s disease

作　　者：顾于蓓[1] 涂蕾[2] 张天宇[1] 钟捷[1] 汪欢 朱良如[2] Gu Yubei;Tu Lei;Zhang Tianyu;Zhong Jie;Wang Huan;Zhu Liangru(Department of Gastroenterology,Ruijin Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200025,China;Department of Gastroenterology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China)

机构地区：[1]上海交通大学医学院附属瑞金医院消化内科,上海200025 [2]华中科技大学同济医学院附属协和医院消化科,武汉430022

出　　处：《中华炎性肠病杂志（中英文）》2021年第3期262-266,共5页Chinese Journal of Inflammatory Bowel Diseases

基　　金：国家自然科学基金(81700490、81873558、82000494);科技部重大专项课题(2018YFC0114604);上海市卫生健康委员会卫生行业临床研究专项面上项目(202040110)。

摘　　要：抗肿瘤坏死因子-α生物制剂已广泛应用于克罗恩病的治疗,目前正有多种新型生物制剂投入临床使用。对于一些合并特殊问题的克罗恩病患者应根据具体情况,充分平衡治疗药物的获益和风险,医患共同决策后选择适合的生物制剂并制定个体化的治疗方案,有助于令患者获得更好的预后。Anti-tumor necrosis factor-αbiologics have been widely used in the treatment of Crohn′s disease.A variety of new biological agents have been approved this year and entered clinical use.Clinical benefits and risks should be fully balanced according to the disease conditions for special population,and shared decision making should be conducted to select appropriate biological agents and develop individualized treatment regimen which will help to improve efficacy and safety of biologics.

关 键 词：克罗恩病 生物制剂 乌司奴单克隆抗体 结核 恶性肿瘤 

分 类 号：R574.62[医药卫生—消化系统]